Search Menu

News

London signed up as a fast-track HIV city by Mayor Sadiq Khan

Simon Collins, HIV i-Base On Wednesday 10 January 2018, Sadiq Khan, the Mayor of London hosted a signing ceremony at City Hall for London to be the second UK city to join the HIV Fast Track City initiative. [1] Other …

2017: a year in review – why i-Base continues…

Polly Clayden and Simon Collins, HIV i-Base A review of 2017 with the most important news and trends. Hyperlinks in the text are to articles from HIV Treatment Bulletin (HTB) in 2017. Great news is always good to report… Steady …

November/December HTB now online

Reports from EACS 2017, 8th HIV and Ageing Workshop and IAS 2017. Plus journal reviews and other news.

1st Dec – Free tickets to “HIV Monologues” at National Gallery Theatre

Please spread the word… Written by community activist Pat Cash, HIV monologues includes moving and powerful performances of four characters, that together show how HIV is relevant now. This is a great chance to see the play in a wonderful …

Early reports from EACS 2017, Milan

EACS 2017, Milan: rapid reports…

Review of evidence supporting modern ART in pregnancy

Why modern HIV meds are safe in pregnancy

September/October HTB now online

ART in pregnancy, U=U, IAS 2017, PrEP in the UK and more…

The evidence for U=U – selected key studies from 20 years of accumulating evidence

The evidence for U=U: why negligible risk is zero risk

ART in pictures (Russian): АРТ в картинках

 АРТ в картинках: Доступно о лечении ВИЧ (1.3 Mb) August 2017 This resource was translated into Russian by the inspirational HIV organisation ITPCru. https://itpcru.org/2017/07/23/art-v-kartinkah-dostupno-o-lechenii-vich/

July/August HTB now online

IAS 2017 conference: 15 reports including new drugs… plus HIV and children, the PrEP IMPACT study in England and shortages of hepatitis vaccines in the UK…

IAS 2017 conference: 23-26 July, Paris

Studies to watch and early reports from the large HIV conference in Paris…

HIV pipeline report 2017: new drugs in development

Next generation of HIV treatments – including studies to watch for at IAS 2017…

May/June HTB now online

Generic abacavir in the UK, Option B+ in Malawi, new HIV pipeline from CROI, new ARVs, selected peer review reports and more…

ART in pictures: HIV treatment explained (June 2017)

Also in Russian. NOTE: this links to the latest update (2021). A new i-Base resource explaining HIV and ART. Read this guide online Download ART in pictures PDF (1.3 Mb) Order print copies (free in UK) This 32-page publication explains HIV and treatment …

Databases for HIV collaboration (DHICE project)

DHICE Project (Databases for HIV: Integration, Collaboration, Engagement) DHICE is a project to encourage collaborative working practice between different HIV cohort projects in the UK. Roy Trevelion, based at i-Base, is the Community Liaison Co-ordinator with the project. Memory works …

March/April HTB now online

Reports from 23rd BHIVA conference on sexual health in the UK, and paediatric and cure-related research from CROI 2017… plus new i-Base appeal…

Pocket ART guide (2017)

Pocket ART is an A7-sized guide to HIV treatment (ART). It is an easy introduction to HIV treatment. Pocket ART guide online Pocket ART guide PDF download Order a free printed copy ART stands for antiretroviral treatment. HIV drugs are …

Hepatitis C – pocket guide (2017)

Pocket hepatitis C (HCV) guide is a small i-Base leaflet about HCV for people who are also HIV positive. It covers testing, monitoring and treatment – especially with new HCV meds called DAAs (direct acting antivirals). Download pocket HCV – PDF (400 Kb) Order …

January/February HTB now online

14 rapid reports from CROI 2017, plus journal reviews and sexual health in the UK – including drop in HIV diagnoses, PrEP news, and HPV vaccines…

Fit for purpose: antiretroviral treatment optimisation (Feb 2017)

Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones. These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects. The ARVs are: dolutegravir (DTG), tenofovir alafenamide …

Post navigation